The Enteric Nervous
System (ENS):
From physiology
to pathology

The Enteric Nervous System (ENS) is now considered as an innovative target to treat numerous pathologies such as metabolic disorders (type 2 diabetes, obesity, NASH), brain pathologies (Alzheimer, Parkinson, depression) and gut dysfunction (pain, diarrhea, constipation). In fact, ENS is composed of billions of neurons that are directly linked to the brain. This “gut-brain” axis is altered during the establishment of pathologies cited above. Therefore, restoring the “gut-brain” axis is the core business of Enterosys.

gut brain axis

Gut-brain axis

Our new concept

Recently, a novel class of molecules, enterosynes, has been discovered. Enterosynes are biological molecules that target ENS to modify the gut-brain axis. Enterosynes could have various origins that included:

Enterosys has developed an innovative platform to identify novel enterosynes from human origin to treat “gut-brain” axis pathologies.

  • Nutrients such as lipids, amino acids, sugars
  • Factors released from microbiota: neurotransmission (serotonin, histamine, GABA,…), short chain fatty acids (acetate, propionate, butyrate), gaseous neurotransmission (NO, H2S)
  • Factors released from the host: gut hormones (GLP-1), neurotransmission (Nitric Oxide, Acetylcholine,…) and neuropeptides (Galanin), epithelial bioactive peptides (Apelin), immune factors (Proinflammatory cytokines, interleukins)

Our drug-discovery platform : easygut

01

Peptidomic analyses

At Enterosys we have accessed to human gut biopsies (healthy and sick patients) to compare and identify the potential relevant peptides disturbed during the targeted pathology. A screening method based on the characteristics of the molecules (chemical nature, structure,…) permits to identify selected hits.

02

Intestinal contractions

We used here an innovative method to measure the intestinal contraction in real-time in experimental models in response to the selected hits. Bioinformatic analysis lead us to identify the impact of hits treatment on intestinal contractions i.e. the effects on amplitude and frequency of contractions. As gut contractions 1) have been disturbed during gut-brain pathologies and 2) can control directly brain neurotransmitters release via an afferent nervous message, this technology reinforces the potential therapeutic actions of these novel enterosynes.

03

Neurotransmitters release

NO is a major neurotransmitter of the gut that has a great impact on gut relaxation. The release of NO is largely disturbed during pathologies, and an efficacious potential treatment must an effect on it. Enterosys has developed a method to measure and analysis the release of Nitric Oxide (NO) in enteric neurons in real-time (in vitro, in vivo) via a specific implanted probe. We use this technology to reinforce and validate the impact of novel molecules on ENS, but also to decipher their mode of action. See our expertise

04

Testing on pathologic model

We have the possibility to test the candidates obtained with our method of selection in different pathologic models. Validate the impact of novel molecules with the right model is of crucial importance to consider a potential treatment. Our method of selection accelerates the development of new hits in preclinical studies, and then optimizes the successfulness of phase I study. (Mettre lien vers feuille expertise)

The Enterosys Portfolio

The example of Diabetes

Enterosys has identified human biomolecules (called EN « x » , EN1 to 8) and compared their efficacy with Metformin (Met) and the enterosyne Galanin (Gal). We have discovered that these biomolecules could have an impact at very low concentrations on duodenal hypercontractility, glucose tolerance, hyperglycemia and body weight.

  • EN1 - First-in-class

    Enterosys Method-of-use Patent pending, identify though collaboration with industrial partner, collaboration for Clinical Phase under discussion

  • EN4 - Best-in-class

    Enterosys Patent under submission, identify with in-house identification & qualification protocol

  • + 6 Bio-molecules

    With qualities to be refined

portfolio table

Oral therapeutic
advantages in type 2 diabetes

diabete advantage

Enterosys

Discover our expertise